Exhibit 99.1 Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrates Profound and Durable Ef icacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB) Biologics License Application Submission of TA-ERT for MPS IIIB Anticipated in First Quarter of 2026 First Patient Dosed in Phase 2 TAMARIND Trial of Tildacerfont for Major Depressive Disorder (MDD) wi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-36279 (Exact name of registrant as specified in its charter) Delaware 75-3175693 (State or other jurisdiction of incorporation or organization) ( ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-35384 | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 14, 2025 (Commission File Number) Delaware 001-41252 81-3777260 (I.R.S. Employer Identification Number) 3017 Bolling Way NE, Floors 1 and 2, Atlanta, Georgia 30305 (Address of principal executive offices, including zip code) Registrant's telephone number, including area code: (404) 806-9 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39402 ANNEXON, INC. (Exact name of Registrant as specified in its Charter) Delaware 27-5414423 (State or other jurisdiction of in ...

Gross Margin increased to 4.4% BURLESON, Texas, August 14, 2025 (ACCESSWIRE) - Sadot Group Inc. (Nasdaq: SDOT) ("Sadot Group", "Sadot" or the "Company"), an emerging player in the global food supply chain sector, today announced its financial results for the second quarter ended June 30, 2025. Chief Executive Officer, Haggai Ravid and Chief Financial Officer, Paul Sansom will host a conference call at 11:00am EDT / 8:00am PDT on August 15, 2025, to review the results. All interested parties are invited to j ...

[Financial & Operational Highlights](index=1&type=section&id=Second%20Quarter%202025%20Financial%20Highlights) Sadot Group achieved its fifth consecutive quarter of positive net income and EBITDA, reporting $114.3 million in consolidated revenues and a 4.4% gross margin Key Financial Metrics | Financial Metric | Value | | :--- | :--- | | Consolidated Revenues | $114.3 million | | Net Income | $0.4 million | | EBITDA | $1.7 million | | Dilutive EPS | $0.07 | | Gross Margin | 4.4% | | Working Capital Surplus | $24.2 million | - Achieved the **fifth consecutive quarter** of **positive net income and EBITDA**[4](index=4&type=chunk) - Completed **26 transactions**, trading over **200,000 metric tons** of agri-commodities across 7 countries[4](index=4&type=chunk) - Gross margins increased to **4.4%**, a **100 basis point** improvement, by focusing on specialty commodities[4](index=4&type=chunk) - Appointed **Haggai Ravid as CEO** (May 28, 2025) and **Paul Sansom as CFO** (August 1, 2025)[4](index=4&type=chunk) - Made a strategic investment, acquiring a **37.5% equity stake** in an Indonesian carbon project focused on peatland and mangrove restoration, expected to generate **1.1 to 1.2 million carbon credits** in its first cycle[4](index=4&type=chunk) [Financial Statements](index=3&type=section&id=Financial%20Statements) The company's financial statements show a decrease in total assets to $130.6 million and a reduction in commodity sales to $114.3 million for the quarter compared to the prior year [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to $130.6 million while total liabilities also declined, leading to an increase in Sadot Group Inc. shareholders' equity to $33.0 million as of June 30, 2025 Condensed Consolidated Balance Sheets Summary | Balance Sheet Items ($'000) | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Total Current Assets** | **118,719** | **152,679** | | **Total Assets** | **130,629** | **164,654** | | **Total Current Liabilities** | **94,526** | **132,170** | | **Total Liabilities** | **94,690** | **132,281** | | **Total Sadot Group Inc. Shareholders' Equity** | **32,980** | **29,193** | | **Total Liabilities and Stockholders' Equity** | **130,629** | **164,654** | [Condensed Consolidated Statement of Operations](index=4&type=section&id=Condensed%20Consolidated%20Statement%20of%20Operations%20and%20Other%20Comprehensive%20Income%2F%20%28Loss%29) Commodity sales decreased to $114.3 million for the three months ended June 30, 2025, resulting in lower gross profit and a net income of $0.4 million attributable to Sadot Group Inc Condensed Consolidated Statement of Operations Summary | Income Statement Items ($'000) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :--- | :--- | :--- | | Commodity Sales | 114,338 | 173,293 | | Gross Profit | 4,987 | 5,788 | | Income from Operations | 1,770 | 2,074 | | Net Income Attributable to Sadot Group Inc. | 389 | 2,369 | | Diluted EPS (Continuing Operations) | $0.08 | $0.45 | [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities totaled $5.4 million for the six months ended June 30, 2025, leading to a decrease in the company's cash balance to $0.4 million Condensed Consolidated Statements of Cash Flows Summary | Cash Flow Items ($'000) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net cash provided by / (used in) operating activities | (5,367) | 10,461 | | Net cash provided by investing activities | — | 3 | | Net cash provided by / (used in) financing activities | 3,978 | (1,940) | | **Net Increase (Decrease) in Cash** | **(1,364)** | **8,602** | | **Cash – end of period** | **422** | **9,956** | [Non-GAAP Financial Measures](index=7&type=section&id=Reconciliations%20of%20EBITDA%20and%20Other%20Non-GAAP%20Measures) The company presents a reconciliation of Net Income to EBITDA, with EBITDA attributable to Sadot Group decreasing to $1.7 million and EBITDA margin contracting to 1.4% for Q2 2025 EBITDA Reconciliation | Reconciliation to EBITDA ($'000) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net income | 286 | 2,317 | | Depreciation and amortization | 27 | 92 | | Interest expense, net | 1,237 | 1,008 | | Income tax expense | — | 5 | | **EBITDA** | **1,550** | **3,422** | | **EBITDA attributable to Sadot Group Inc.** | **1,653** | **3,474** | | **EBITDA margin attributable to Sadot Group Inc.** | **1.4 %** | **2.0 %** | [About Sadot Group Inc.](index=2&type=section&id=About%20Sadot%20Group%20Inc.) Sadot Group Inc. operates in the global food supply chain, providing sustainable solutions through agri-commodity trading and farm operations in Southern Africa - Sadot Group is an emerging player in the **global food supply chain**, focused on **sustainable solutions**[7](index=7&type=chunk) - Operates in two main verticals: **global agri-commodity origination/trading** and **farm operations in Southern Africa**[8](index=8&type=chunk) - Connects producers from the **Americas, Africa, and the Black Sea** with consumers in **Southeast Asia, China, and the MENA region**[9](index=9&type=chunk) [Forward-Looking Statements](index=8&type=section&id=Forward-Looking%20Statements) This section provides a standard legal disclaimer regarding forward-looking statements, advising readers to consult SEC filings for associated risks and uncertainties - The press release includes forward-looking statements under the "safe harbor" provisions of U.S. law[19](index=19&type=chunk) - These statements are **not guarantees of future performance** and are **subject to risks and uncertainties**[19](index=19&type=chunk) - The company **does not undertake a duty to update these statements**[19](index=19&type=chunk)

News Summary Exhibit 99.1 Sandisk Reports Fiscal Fourth Quarter 2025 Financial Results MILPITAS, Calif. — August 14, 2025 — Sandisk Corporation (Nasdaq: SNDK) today reported fiscal fourth quarter financial results. "Sandisk delivered strong results this quarter, with revenue and non-GAAP EPS exceeding our guidance. We continue to execute with discipline, balancing innovation and operational focus," said David Goeckeler, Sandisk CEO. "The ramp of BiCS8 brings new levels of performance, density and energy eff ...

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right (CVR), plus a 2.5% royalty on future net sales of UNLOXCYT™ (cosibelimab-ipdl) FDA accepted New Drug Application filing for priority review of CUTX-101 to treat Menkes disease; PDUFA goal date of September 30, 2025 E ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36745 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) | Delaware | 59-2262718 | | --- | ...